Stock of the Day

May 9, 2024

Emergent Biosolutions (EBS)

$6.06
+$0.15 (+2.5%)
Market Cap: $303.02M

About Emergent Biosolutions

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Today's Trend

Emergent BioSolutions Inc. (NYSE: EBS) shares have sold off as investors weighed better-than-expected quarterly revenue against a substantial impairment charge and renewed legal scrutiny.

  • Emergent reported approximately $234 million in quarterly revenue, exceeding its prior guidance and the consensus estimate of $177.5 million. The company also reported adjusted EPS of $0.60, well above expectations for a loss. Emergent BioSolutions Q2 2026 Earnings Call Transcript
  • HC Wainwright reiterated a Buy rating and a $10 price target, forecasting a return to profitability in 2027 with estimated full-year EPS of $0.28. However, the firm still expects a $4.63-per-share loss for fiscal 2026.
  • Zacks Research upgraded Emergent BioSolutions to Hold, suggesting a more balanced view of the stock’s risk and recovery prospects. Zacks Research
  • The company recorded a $191.3 million non-cash impairment on its NARCAN franchise. Emergent attributed the charge to increased competition and pricing pressure in naloxone, raising concerns about the product’s future revenue and profitability. EBS Investor Alert
  • Levi & Korsinsky announced an investigation into potential securities-law violations related to the company’s disclosures and the NARCAN impairment. The investigation does not establish wrongdoing, but it adds legal and reputational risk following the earnings announcement. Levi & Korsinsky Investigation
← Previous Stock of the DayNext Stock of the Day →

Recent News